Skip to main content
LGVN
NASDAQ Life Sciences

Longeveron CFO Lisa Locklear to Step Down, Controller Marie Washburn Expected to Take Role

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$0.73
Mkt Cap
$23.092M
52W Low
$0.475
52W High
$1.8
52W Position info
54% above low
Off High info
59% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

LGVN sits 54% above its 52-week low of $0.475 on light trading volume (0.1× avg).

Summary

Longeveron Inc. announced that CFO Lisa Locklear will depart on July 10, 2026, with current controller Marie Washburn expected to be appointed as her successor.


Key Events · Executive and Board Changes · LGVN

  • CFO Departure Announced

    Lisa Locklear will step down from her role as Chief Financial Officer, effective July 10, 2026.

  • Succession Plan in Place

    Marie Washburn, the company's current controller, is anticipated to be elevated to the CFO role upon Ms. Locklear's departure.

  • Amicable Resignation

    Ms. Locklear's resignation was not due to any disagreement with the company, but rather to pursue other professional and personal interests.


Analysis · LGVN · Life Sciences

The departure of a Chief Financial Officer, even if amicable, introduces an element of leadership transition at a critical time for Longeveron, which is facing significant financial and regulatory challenges, including a 'going concern' warning and a proposed reverse stock split. The anticipated internal promotion of the current controller to CFO provides some continuity, but the change still warrants attention given the company's precarious situation.

How filings like this one have moved

In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LGVN was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.1M. The 52-week trading range was $0.48 to $1.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LGVN - Latest Insights

LGVN
Aug 24, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.750
Real-time Price: $6.92 info
Change: Reverse Stock Split info
Market Cap: $31.087M info
LGVN
Aug 24, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7325
Real-time Price: $6.92 info
Change: Reverse Stock Split info
Market Cap: $31.087M info
LGVN
Aug 12, 2026, 4:22 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.6835
Real-time Price: $6.92 info
Change: Reverse Stock Split info
Market Cap: $31.087M info
LGVN
Aug 12, 2026, 4:14 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.680
Real-time Price: $6.92 info
Change: Reverse Stock Split info
Market Cap: $31.087M info
LGVN
Aug 12, 2026, 4:03 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.682
Real-time Price: $6.92 info
Change: Reverse Stock Split info
Market Cap: $31.087M info